Exchange: NASDAQ·Updated 03:28 PM EDT
News
all
press releases
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.
Zacks
More News
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of +29.13% and +18.23%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ultragenyx Q2 Loss Narrows, Reaffirms 2026 Revenue Outlook
(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a narrower net loss for the second quarter, as revenues grew from a year ago. The company reaffirmed its full-year 2026 revenue guidance...
Nasdaq News: Markets
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading
Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.
Stocktwits
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
Zacks
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)
Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE...
Yahoo! Finance: News

Advertisement|Remove ads.